Ocular hypertension
Therapeutic area
Ophthalmology
Rare disease
No
- Definition
- Abnormally high intraocular pressure.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Ocular hypertension
- Alternative names
- ocular hypertension
- Therapeutic area
- Ophthalmology
- Severity
- Mild
- Cardiology
- Ophthalmology
- Vascular Medicine
- MONDO ID
- MONDO:0006875
- Parent condition
- MONDO:0005044
Related records
Broader conditions (10)
- Arterial disorder
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Disorder of orbital region
- Disorder of visual system
- Eye disorder
- Human disease
- Hypertensive disorder
- Vascular disorder
Trials (650)
- [KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
- 1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
- 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
- 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
- 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.
- 24-hour Efficacy of AR-12286
- 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients
- 24-hour IOP-lowering Effect of 0.01% Bimatoprost
- 24-hour IOP-lowering Effect of Brimonidine 0.1%
- 24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
- 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
- A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma
- A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
- A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
- A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma
- A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
- A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
- A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
Approved drugs (14)
- Betaxolol hydrochloride
- Bimatoprost
- Brimonidine tartrate
- Brinzolamide
- Dorzolamide hydrochloride
- Latanoprost
- Latanoprostene bunod
- Netarsudil dimesylate
- Omidenepag isopropyl
- Pilocarpine
- Tafluprost
- Timolol
- Timolol maleate
- Travoprost
Drugs in development (19)
- AMA0076 Phase 2
- AZD-4017 Phase 2
- Bamosiran Phase 2
- Betaxolol Phase 3
- Bimatoprost grenod Phase 1
- Brimonidine Phase 3
- DE-104 Phase 2
- Dorzolamide Phase 3
- Evodenoson Phase 1
- Levobetaxolol hydrochloride Phase 3
- Ofloxacin Phase 3
- Phenylephrine Phase 1
- Piclidenoson Phase 2
- Prednisolone Phase 3
- SAD448 Phase 1
- Simenepag isopropyl Phase 2
- Trabodenoson Phase 3
- Tropicamide Phase 1
- Verosudil Phase 2
Other linked drugs (4)
- Carteolol
- Carteolol hydrochloride
- Netarsudil
- Ripasudil hydrochloride dihydrate